BlackRock, Inc. has increased its stake in Olin Corp., now owning 11.5% of the company's common stock. This significant ownership change was disclosed in a recent filing, highlighting BlackRock's ongoing strategic interest in the chemicals sector.
The filing, dated November 4, 2026, indicates that BlackRock beneficially owns 13,058,352 shares of Olin Corp., with 12,867,129 shares having sole voting power. This move is part of BlackRock's broader investment strategy, as the firm continues to position itself within key industries.
Background
BlackRock, Inc. is a leading global investment management firm, classified under the SIC code 6211, which pertains to Security Brokers, Dealers & Flotation Companies. The company is listed on the New York Stock Exchange under the ticker symbol BLK. Recent filings include multiple Schedule 13G/A submissions, indicating active management of its investment portfolio.
What the Filing Says
The filing states, "This Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units of BlackRock, Inc. and its subsidiaries and affiliates." This highlights the firm's structured approach to managing its investments and complying with regulatory requirements.
Impact
This increase in ownership may affect various stakeholders, including Olin Corp.'s management and existing shareholders. Institutional investors like BlackRock often bring a level of scrutiny and expectations regarding corporate governance and performance. The filing also notes that the iShares Core S&P Small-Cap ETF, a BlackRock entity, holds more than five percent of Olin's outstanding shares, further emphasizing the firm's significant influence in the market.
What's Next
The filing does not say what happens next, but BlackRock's increased stake could lead to further engagement with Olin Corp.'s management regarding strategic decisions and corporate governance.
Read Next
Wassil Jim Reports Stock Transactions for Vaxcyte, Inc.
Cowan Elvia Reports Stock Transactions in SEC Filing
Saiki Julie Reports New Stock Transactions at Azora Therapeutics
Davidson Acquires Over 524,000 Shares of Azora Therapeutics
CBL & Associates Properties Announces New Stock Buyback Plan
Rothblatt amends Schedule 13G, reveals 4% stake in United Therapeutics






